

VentriPoint Diagnostics Retains Russo Partners as Communications Counsel

SEATTLE, Feb. 13, 2008 – VentriPoint™ Diagnostics Ltd. (TSX: VPT) today announced that, pending regulatory approval, it has entered into an agreement with Russo Partners of New York to lead its investor and media relations activities.

Russo Partners will work with VentriPoint's executives to increase the company's public profile with potential and existing investors. It will also help raise awareness of the VentriPoint Diagnostic System with medical professionals and provide an understanding of VentriPoint's research programs. Russo Partners will initiate its work with a thorough analysis and update of VentriPoint's communications tools and implement an ongoing communications program. In addition, Russo Partners will coordinate VentriPoint's investor relations activities and lead efforts to regularly update the investment community about VentriPoint's developments.

“Russo Partners has a sterling reputation with relevant backgrounds in both the life sciences and communications community to help us refine our messaging and implement a strategic communications plan,” said Joseph Ashley, founder and chief executive officer of VentriPoint. “We are excited to be working with them as we continue development of the VentriPoint Diagnostic System.”

VentriPoint has retained Russo Partners for an initial period of six months which term automatically renews unless cancelled by one of the parties with 60 days notice. Minimum fees totaling \$63,000 are to be paid by VentriPoint to Russo Partners during the initial term of the agreement, with the full amount of the fees being dependant upon the total services to be provided..

About Russo Partners

Russo Partners LLC, formerly Noonan Russo, provides strategic communications services to emerging healthcare – biotech, medical device, diagnostics and healthcare services – companies worldwide. For more information, visit www.russopartnersllc.com.

About VentriPoint Diagnostics

VentriPoint is a clinical diagnostic company based in Seattle that commenced operations in January 2005 with a view to commercializing innovative and patented imaging technologies developed by the University of Washington (the "Technology"). Applying this Technology, VentriPoint is attempting to develop a breakthrough diagnostic tool for the rapid and cost effective measurement of a heart's volume and ventricular ejection fractions (blood flow), which Technology, together with its associated online service, will be extendable to a variety of heart related disease states.

For further information, please contact:

Edward Garth, Chief Financial Officer
VentriPoint Diagnostics Ltd.
Telephone: (206) 283-0221
Facsimile: (206) 283-2309

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

(Not for dissemination in the United States of America)

###